ERBB2 and breast carcinoma: Early-stage tumors that are estrogen receptor (ER) positive and ERBB2 (formerly HER2/neu) (OMIM 164870) negative comprise 70% of breast cancer diagnoses, and a survival disparity according to race and ethnicity among patients with this disease subtype is well documented.5